[go: up one dir, main page]

SI2252597T1 - Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze - Google Patents

Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze

Info

Publication number
SI2252597T1
SI2252597T1 SI200930949T SI200930949T SI2252597T1 SI 2252597 T1 SI2252597 T1 SI 2252597T1 SI 200930949 T SI200930949 T SI 200930949T SI 200930949 T SI200930949 T SI 200930949T SI 2252597 T1 SI2252597 T1 SI 2252597T1
Authority
SI
Slovenia
Prior art keywords
protein kinase
kinase inhibitors
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
SI200930949T
Other languages
English (en)
Inventor
Jensen Annika Jenmalm
Fredrik Lehmann
Bjorn M. Nilsson
Erik Nordling
Vendela Parrow
Original Assignee
Akinion Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akinion Pharmaceuticals Ab filed Critical Akinion Pharmaceuticals Ab
Publication of SI2252597T1 publication Critical patent/SI2252597T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200930949T 2008-02-01 2009-01-28 Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze SI2252597T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0800250 2008-02-01
US12303908P 2008-04-04 2008-04-04
SE0801185 2008-05-21
EP09706385.3A EP2252597B1 (en) 2008-02-01 2009-01-28 Pyrazine derivatives and their use as protein kinase inhibitors
PCT/EP2009/050931 WO2009095399A2 (en) 2008-02-01 2009-01-28 Pyrazine derivatives and their use as protein kinase inhbitors

Publications (1)

Publication Number Publication Date
SI2252597T1 true SI2252597T1 (sl) 2014-07-31

Family

ID=40527384

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930949T SI2252597T1 (sl) 2008-02-01 2009-01-28 Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze

Country Status (19)

Country Link
US (2) US8436171B2 (sl)
EP (2) EP2671876A3 (sl)
JP (2) JP5562256B2 (sl)
KR (1) KR101599082B1 (sl)
CN (1) CN101970418B (sl)
AU (1) AU2009209633C1 (sl)
BR (1) BRPI0907453A2 (sl)
CA (1) CA2713553A1 (sl)
CY (1) CY1115400T1 (sl)
DK (1) DK2252597T3 (sl)
ES (1) ES2459297T3 (sl)
HK (1) HK1149268A1 (sl)
HR (1) HRP20140547T1 (sl)
MX (1) MX2010007973A (sl)
PL (1) PL2252597T3 (sl)
PT (1) PT2252597E (sl)
RU (1) RU2493152C2 (sl)
SI (1) SI2252597T1 (sl)
WO (1) WO2009095399A2 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2252597T3 (pl) * 2008-02-01 2014-09-30 Akinion Pharmaceuticals Ab Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
WO2013089636A1 (en) * 2011-12-15 2013-06-20 Akinion Pharmaceuticals Ab Processes for manufacturing of a kinase inhibitor
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
SMT201800037T1 (it) 2012-04-17 2018-03-08 Fujifilm Corp Composto eterociclico contenente azoto o suo sale
US20130310387A1 (en) * 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
CA2927079C (en) 2013-10-16 2017-05-23 Fujifilm Corporation Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor
JP2017523972A (ja) 2014-07-31 2017-08-24 アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） Ｆｌｔ３レセプターアンタゴニスト
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN110483366B (zh) * 2018-05-14 2022-09-16 中国医学科学院药物研究所 吲哚类化合物及其制备方法、药物组合物和用途
CN113924095A (zh) * 2019-01-18 2022-01-11 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
EP3911325A4 (en) * 2019-01-18 2022-10-12 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112574192B (zh) * 2020-12-24 2021-10-01 烟台大学 氨基酸衍生联噻唑-色胺类抗癌化合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (sl) * 1992-04-03 1994-06-21 Ciba Geigy Ag
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
MXPA06003615A (es) * 2003-09-30 2006-06-05 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
US20080194574A1 (en) 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
ATE458730T1 (de) * 2004-04-13 2010-03-15 Icagen Inc Polycyclische pyrazine als kaliumionenkanal- modulatoren
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
ATE517868T1 (de) * 2006-08-16 2011-08-15 Boehringer Ingelheim Int Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
DK2848610T3 (da) 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
PL2252597T3 (pl) * 2008-02-01 2014-09-30 Akinion Pharmaceuticals Ab Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych

Also Published As

Publication number Publication date
ES2459297T3 (es) 2014-05-08
HRP20140547T1 (hr) 2014-07-18
PT2252597E (pt) 2014-04-30
EP2671876A3 (en) 2014-02-05
US8436171B2 (en) 2013-05-07
PL2252597T3 (pl) 2014-09-30
EP2252597B1 (en) 2014-03-19
AU2009209633B2 (en) 2013-07-18
WO2009095399A3 (en) 2009-10-01
DK2252597T3 (da) 2014-04-28
RU2493152C2 (ru) 2013-09-20
US20110098310A1 (en) 2011-04-28
EP2671876A2 (en) 2013-12-11
JP2014148522A (ja) 2014-08-21
BRPI0907453A2 (pt) 2015-07-14
KR20100116599A (ko) 2010-11-01
US20130203774A1 (en) 2013-08-08
RU2010136653A (ru) 2012-03-10
CY1115400T1 (el) 2017-01-04
CN101970418B (zh) 2013-07-03
JP2011510948A (ja) 2011-04-07
EP2252597A2 (en) 2010-11-24
CN101970418A (zh) 2011-02-09
JP5562256B2 (ja) 2014-07-30
CA2713553A1 (en) 2009-08-06
WO2009095399A2 (en) 2009-08-06
MX2010007973A (es) 2010-11-09
HK1149268A1 (en) 2011-09-30
AU2009209633C1 (en) 2014-01-23
AU2009209633A1 (en) 2009-08-06
KR101599082B1 (ko) 2016-03-02

Similar Documents

Publication Publication Date Title
SI2252597T1 (sl) Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
HUS1900014I1 (hu) Proteinkináz inhibitorok
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
ZA201004243B (en) Benzofuropyrimidinones as protein kinase inhibitors
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
IL197231A0 (en) Pyrimidines derivatives and their use as kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
ZA201201703B (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
HK1158947A1 (en) Macrocyclic pyrimidines as protein kinase inhibitors
IL233040A0 (en) Pyridine and pyrazine derivatives as protein kinase modulators
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL210073A0 (en) Protein kinase inhibitors
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL207415A0 (en) Protein kinase inhibitors and use thereof
ZA201003420B (en) Protein kinase inhibitors and use thereof
IL210069A0 (en) Protein kinase inhibitors
EP2432473A4 (en) PYRAZOLOPYRIMIDINES AND HETEROCYCLES ASSOCIATED AS KINASE INHIBITORS
ZA201008387B (en) Azacarboline derivatives,preparation thereof,and therapeutic use thereof as kinase inhibitors
HU0900798D0 (en) 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA201002885B (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors